Patient Identification for Clinical Trials – The Case of HLA & Antigen-Specific Immunotherapy in Type 1 Diabetes

Time: 9:30 am
day: Day Two


• Retrospective and prospective clinical data show that individuals carrying HLA variants associated with autoimmunity against GAD (glutamic acid decarboxylase) respond to GAD-specific immunotherapy, supporting the notion of precision medicine in Type 1 diabetes
• By prescreening for the presence of HLA DR3-DQ2, the HLA haplotype associated with GAD-specific autoimmunity, individuals that have a high likelihood of responding to GAD-specific immunotherapy can be selected for clinical trials
• This approach is now being evaluated in a confirmatory Phase III trial in Europe and the United States